FDA clears antimicrobial blood pressure cuff:
This article was originally published in Clinica
Executive Summary
Vital Signs has received US FDA 510(k) clearance to market its antimicrobial-treated, single-patient-use blood pressure cuff. The Cuffable Plus device, which is impregnated with an antimicrobial agent, could help combat the cross contamination that leads to hospital-acquired infections, said the Totowa, New Jersey-based company. Noting that the US market for single-patient-use blood pressure cuffs is approaching $30 million, Vital said its antimicrobial enhancement would help it advance its number two market position.
You may also be interested in...
Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
Hair Supplement Linked To Cases Of Severe Hepatitis In France
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: